BMO Capital Maintains Market Perform on Novo Nordisk, Lowers Price Target to $40

Benzinga · 4d ago
BMO Capital analyst Evan David Seigerman maintains Novo Nordisk (NYSE:NVO) with a Market Perform and lowers the price target from $47 to $40.